The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Sorafenib or 90Y loaded resin microsphere radioembolization for locally-advanced hepatocellular carcinoma, what should we trust?
Garin E1, Rolland Y, Edeline J. Liver Int. 2015 Feb 18. doi: 10.1111/liv.12811. [Epub ahead of print]
Author information
1Cancer Institute Eugène Marquis, Nuclear Medicine Department, CS 44229, F-35042, Rennes, France; University of Rennes 1, F-35043, Rennes, France; INSERM U991 Liver Metabolisms and Cancer, F-35033, Rennes, France.
Abstract
First of all, from a semantic point of view, the use of the term "90Y radioembolization" is not entirely suitable. It is now well known that resin and glass 90Y-loaded microspheres possess different radiobiological properties (2) due to their highly different specific activities, namely with 50 Bq for resin microspheres versus 2500 Bq for glass microspheres, as well as the different amounts of spheres injected. Thus, just as for the drug used the product used for radioembolization must therefore be precisely defined, especially in the title or abstract, in order to avoid misinterpretation.